KALV
NASDAQ · Biotechnology
Kalvista Pharmaceuticals Inc
$17.00
+0.57 (+3.47%)
Open$16.79
Previous Close$16.43
Day High$17.21
Day Low$16.27
52W High$19.00
52W Low$9.24
Volume—
Avg Volume674.6K
Market Cap819.36M
P/E Ratio—
EPS$-2.95
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+280.9% upside
Current
$17.00
$17.00
Target
$64.76
$64.76
$35.35
$64.76 avg
$75.74
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 272.43M | 275.70M | 294.93M |
| Net Income | -77,974,346 | -85,417,882 | -94,496,772 |
| Profit Margin | -28.6% | -31.0% | -32.0% |
| EBITDA | -125,574,606 | -125,457,307 | -124,623,061 |
| Free Cash Flow | -59,177,907 | -68,220,346 | -69,677,831 |
| Rev Growth | +3.3% | +15.2% | -10.0% |
| Debt/Equity | 0.07 | 0.09 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |